 | Amplimed CorporationAmpliMed Corporation, a clinical-stage pharmaceutical company founded by world-renowned oncologists, has a lead compound, Amplimexon®, in Phase II clinical trials, with early evidence of efficacy and low levels of toxicity. The Company also has two other promising drug candidates, benzimate, which entered Phase I clinical study during 2006, and Amplizone™, which is scheduled to begin Phase I studies in 2007. The Company is focused on the development of small-molecule oncology drugs with novel mechanisms of action. |
 | Angstrom Pharmaceuticals, Inc.Ångstrom's proprietary products target a clearly-defined pathway, the Urokinase Plasminogen Activation System (PA), which has repeatedly been shown in scientific literature to be directly involved in proliferative diseases, such as cancer and wet age-related macular degeneration (ARMD). |
 | CellzDirect, Inc.The mission of CellzDirect is to build a preeminent biotechnology company that develops innovative in vitro products and services and provides rapid, accurate data with valid interpretations to accelerate the discovery and development of bioavailable, safe and efficacious drugs. CellzDirect was sold to Invitrogen Corporation in 2008. |
 | High Throughput Genomics, Inc.High Throughput Genomics, Inc. (HTG), established in 1997, is a privately held company with a corporate mission to develop a universal molecular biology-based tool set to improve the pharmaceutical drug discovery process. |
 | ImaRx TherapeuticsImaRx Therapeutics is a biopharmaceutical company that develops and commercializes therapies for vascular disorders. ImaRx's commercialization efforts are currently focused on Abbokinase®, their product approved by the U.S. Food and Drug Administration, or FDA, for the treatment of acute massive pulmonary embolism, or blood clots in the lungs. |
 | PhotoTheraPhotoThera develops NeuroThera, a proprietary Infrared Laser Therapy (ILT) technology that administers a highly effective non-invasive treatment for victims of ischemic stroke. |
 | Regenesis Biomedical, Inc.Regenesis Biomedical, Inc. developed and markets the Provant® Wound Therapy System, the exciting new scientifically proven approach that is redefining the care of soft tissue wounds. |
